,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'breast', 'destiny-breast04']
 destiny-breast04: t-dxd vs chemo for her2-low hr+ #metastaticbreastcancer 52.6% vs 16.3% 10.1 vs 5.4 mo 0.51 23.9 vs 17.5 mo 0.64 grade 3+ aes were more frequent in chemo arm ild rate 12.1% #asco22 #bcsm 
Physician Scientist/Breast Oncology specialist @mdandersonnews - ????????Views are mine; Retweet ? endorsement; Scientific advisory board member @LobularBCA